Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.


Panel:   Vancomycin-Resistant Enterococci (VRE)
AR Bank # 0791 Enterococcus faecalis
Study ID: VRE-11

Biosample Accession #: SAMN15040090

   
MLST: ST62(Pasteur)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Vancomycin-Resistant Enterococci (VRE)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Ampicillin 1S
Chloramphenicol 8S
Daptomycin 1S
Doxycycline 4S
High-Level Gentamicin 2<=500SYN-S
High-Level Streptomycin 2<=1000SYN-S
Levofloxacin 1S
Linezolid 2S
Penicillin 2S
Quinupristin/dalfopristin 1 31R
Rifampin 1S
Teicoplanin 0.5S
Vancomycin 1S
SDD (Susceptible Dose Dependent)
S – I –R Interpretation (INT) derived from CLSI 2022 M100 S32

1 Reflects MIC of first component
2 SYN-S: is synergistic with cell-wall active agent (e.g., ampicillin, penicillin and vancomycin) if the cell-wall active agent is also susceptible
3 The MIC Interpretation has been defaulted to "Resistant" due to known intrinsic resistance for this bacterial species in the wild-type population. [See Appendix B, Intrinsic Resistance; CLSI M100]
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Glycopeptides VanB
Tetracyclines tet(M)
 
Disclaimer:
AR gene prediction was performed using ARG-ANNOT, ResFinder and NCBI (ResGANNCBI) databases accessed on 2022-09-15. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of used database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. *MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacteriaceae, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified and "submitted". Dash (-) indicates no pubMLST scheme is available for that species.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
11/20/23Sequence Accession # changed: from '---' to 'SAMN15040090'
06/06/23MLST was updated: from '---' to 'ST62(Pasteur)'
06/05/23Gene was added to 'tet(M)'
06/05/23Gene was added to 'VanB'
06/05/23Category was added: 'Tetracyclines'
06/05/23Category was added: 'Glycopeptides'
02/14/23Drug was removed: 'Omadacycline'
02/14/23INT was updated with a new value for Daptomycin: from 'SDD' to 'S'
02/14/23INT was updated with a new value for Omadacycline: from '---' to 'S'
02/14/23MIC was updated with a new value for Omadacycline: from '---' to '0.25'
02/14/23Drug was added: Omadacycline
02/14/23INT was updated with a new value for Daptomycin: from 'S' to 'SDD'
02/14/23MIC was updated with a new value for Omadacycline: from '---' to '0.25'
11/20/18New Isolate added to panel
Top of Page
TOP